Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, Price A.

J Clin Oncol. 2009 Mar 10;27(8):1220-6. doi: 10.1200/JCO.2008.19.3995. Epub 2009 Jan 21.

2.

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

Lee CP, de Jonge MJ, O'Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J.

Clin Cancer Res. 2006 May 1;12(9):2841-8.

3.

A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer.

Davidson NG, Chick JB, Perren TJ, Campbell N, Thompson JM, Chan YT.

Clin Oncol (R Coll Radiol). 1996;8(6):358-62.

PMID:
8973850

Supplemental Content

Loading ...
Support Center